Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz 400 mg vs 600 mg in HIV/TB Co-infection (EDOSE)
NCT04513379Phase 3Unknown
- Start
- Nov 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of efavirenz in human immunodeficiency virus infection (HIV). Status: unknown.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04513379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513379.